KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Arbutus Biopharma (ABUS) over the last 15 years, with Q3 2025 value amounting to $11.1 million.

  • Arbutus Biopharma's Other Non-Current Liabilities rose 3317.34% to $11.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.1 million, marking a year-over-year increase of 3317.34%. This contributed to the annual value of $10.2 million for FY2024, which is 3453.95% up from last year.
  • As of Q3 2025, Arbutus Biopharma's Other Non-Current Liabilities stood at $11.1 million, which was up 3317.34% from $10.8 million recorded in Q2 2025.
  • In the past 5 years, Arbutus Biopharma's Other Non-Current Liabilities registered a high of $19.4 million during Q1 2021, and its lowest value of $7.6 million during Q4 2023.
  • For the 5-year period, Arbutus Biopharma's Other Non-Current Liabilities averaged around $11.9 million, with its median value being $10.5 million (2025).
  • In the last 5 years, Arbutus Biopharma's Other Non-Current Liabilities plummeted by 3921.89% in 2023 and then surged by 3500.0% in 2025.
  • Arbutus Biopharma's Other Non-Current Liabilities (Quarter) stood at $16.3 million in 2021, then plummeted by 36.4% to $10.4 million in 2022, then fell by 26.68% to $7.6 million in 2023, then skyrocketed by 34.54% to $10.2 million in 2024, then rose by 8.56% to $11.1 million in 2025.
  • Its Other Non-Current Liabilities was $11.1 million in Q3 2025, compared to $10.8 million in Q2 2025 and $10.5 million in Q1 2025.